Navigation Links
Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
Date:3/21/2011

NEW YORK, March 21, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Global Angiongenesis Inhibitors and Stimulators Industry

http://www.reportlinker.com/p0459142/Global-Angiongenesis-Inhibitors-and-Stimulators-Industry.html

This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following product segments - Angiogenesis Inhibitors, and Angiogenesis Stimulators. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 72 companies including many key and niche players worldwide such as Abbott Laboratories, Adnexus Therapeutics, Inc., AEterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, and ThromboGenics Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability And Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions And Scope Of Study 3

1. Angiogenesis Inhibitors 4

2. Angiogenesis Stimulators 4

2. MARKET OUTLOOK 5

Angiogenesis: In the Spotlight 5

Angiogenesis: A Preview 5

Analysis by Region 5

US: The Single Largest Market 5

Angiogenesis Regulating Products Market in Europe 6

Market for Angiogenesis Regulating Products in Rest of World 6

Table 1: Global Market for Angiogenesis Regulating Products

(2009-2015): Geographic Regions Ranked by CAGR - USA,

Europe, and Rest of World (includes corresponding

Graph/Chart) 6

Selective Analysis of Angiogenesis Regulating Products 6

3. MARKET OVERVIEW 7

Angiogenesis Makes Inroads 7

Angiogenesis: Ushering-In a New Era 7

Angiogenesis: Fact File 8

Milestones in Research Achieved Over the Years 9

Anti-Angiogenic Drugs Market - An Overview 10

Angiogenic Inhibitors Market to Surge 10

The Long Journey for Anti-Angiogenesis Therapies 10

Approved Anti-Angiogenesis Drugs in the Market 11

Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In

Oncology By Type 11

Small Molecule Tyrosine Kinase Inhibitors 12

Inhibitors of mTOR 13

Other Anti-Angiogenic Agents 13

Leading Drugs in the Market 14

Avastin Leads the Fray 14

Table 2: Select Leading Drugs in the Global

Anti-Angiogenesis Market: Annual Sales in US$ Million for

Years 2008 & 2009 (includes corresponding Graph/Chart) 14

Overview of Select Leading Drugs 15

Avastin 15

Survival Benefit Conferred by Avastin 16

Mechanism of Action 17

General Mode of Delivery 17

Side Effects Elicited on Administering Avastin 17

ERBITUX™ (Cetuximab) 17

Regulatory Approvals 18

Erbitux in Head and Neck Cancer 18

Glivec/Gleevec (imatinib mesylate) 19

Herceptin (Tractuzumab) 19

Iressa (gefitinib) 19

Sutent (Sunitinib) 20

Other Regulatory Approvals 20

Sunitinib in Various Indications 20

Sunitinib in Renal Cell Carcinoma (RCC) 20

Sutent in Gastrointestinal Stromal Tumors 21

Cost Related Issues 21

Tarceva (Erlotinib) 21

Other Regulatory Approvals 22

Thalomid® (thalidomide) 22

Table 3: Thalomid - Percentage Breakdown Based on Relative

Oncology Application (includes corresponding Graph/Chart) 22

Cilengitide 23

Imiquimod 23

Angiogenesis Inhibitors - Pipeline Status 24

Select Anti-Angiogenesis Drugs in Phase III Development 24

Select Anti-Angiogenesis Drugs in Phase II Development 25

Select Anti-Angiogenesis Drugs in Phase I Development 26

Approved and Pipeline Indications of Select Anti-VEGF/VEGFR

Drugs 26

Novel Targets for Anti-Angiogenic Activity 27

Approved and Pipeline HER Receptor-Targeting Drugs 28

Select Approved and Pipeline m-TOR Inhibitors 28

Integrins 28

Select Integrin Targeting Drugs Under Development 29

Angiogenic Inhibitors - By Disease Application 29

Cancer 29

Various Types of Cancers Targeted by Angiogenesis

Inhibitors in Phase III Clinical Development 29

Diabetic Retinopathy 30

Female Reproductive Cycle 30

Psoriasis 30

Inflammatory Diseases 30

Table 4: Classification of Anti-Angiogenic Compounds Based

on Most Commonly Targeted Indication (includes

corresponding Graph/Chart) 31

Angiogenesis Inhibitors in Eye Related Diseases 31

Age-Related Macular Degeneration 31

Wet AMD 32

Dry AMD 32

Select Anti-Angiogenic Drugs Approved by FDA for Treatment

of Eye Diseases 32

Angiogenesis Inhibitors in Dermatology 33

Select Drugs/Therapeutics with Angiogenic Mode of Action

Approved by FDA for Dermatology 33

4. MARKET TRENDS 34

Cancer - The Key Target Indication for Research in Anti-

Angiogeneis Drugs 34

Avastin Continues to Record Robust Growth 34

New Markets Offer Higher Potential for Herceptin 34

Increased Use Drives Tarceva's Growth in Developed Markets 34

Angiogenesis Inhibitors Continue to Dominate RCC Drug Market 35

Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market 35

Table 5: Leading Drugs in the Global Second Line Advanced

Renal Cell Carcinoma Market (2009): Percentage Breakdown by

Value Sales for Nexavar, Torisel, Afinitor, Avastin, and

Others (includes corresponding Graph/Chart) 36

Clinical Benefits of Votrient Over Sutent 36

Avastin's Approval for Breast Cancer Treatment Under Threat 37

5. ANGIOGENESIS REPERTOIRE 38

An In-depth Insight into Angiogenesis 38

Angiogenesis: At a Glance 38

Requisites for Angiogenesis 38

Endogenous Regulators of Angiogenesis 39

Angiogenic Process: Sequence of Events 39

Angiogenesis Process in Children 40

Angiogenesis Process in Adults 40

The Process of Angiogenesis in Thyroid Gland 40

6. ANGIOGENESIS INHIBITORS 41

Table 6: Global Market for Angiogenesis Inhibitors

(2009-2015): Geographic Regions Ranked by CAGR - USA, Europe,

and Rest of World (includes corresponding Graph/Chart) 41

Angiogenic Inhibitors: Basic Framework 41

Natural Inhibitors 41

Thrombospondin 41

Interferon 41

Cryptic Inhibitors 42

Other Natural Inhibitors 42

Natural Sources for Anti-Angiogenic Action 42

Potential Anti-Angiogenic Drugs of Natural Origin 42

Angiogenic Inhibitors: On the Verge of Attaining Superior

Clinical Efficacy 42

Endogenous vs Synthetic Agents 43

Angiogenesis Inhibitors: Classification Based on Source of

Origin 43

Anti-Angiogenic Molecules: Classification Based on Mode of

Action 44

Broad Overview of Anti-Angiogenic Therapies 44

Pre-Requisites for Any Drug to be an Angiogenic Inhibitor 44

Specific Therapeutic Strategies of Anti- Angiogenesis Agents 45

Inhibiting Angiogenesis In Vivo 45

Antiangiogenic Tumor Therapy 46

Antivascular Therapy: Adding a New Dimension 46

MMPs - Exhibiting Dual Role 46

Angiogenesis Inhibitors Vs Standard Chemotherapy 47

Comparison Between Cytostatic Antiangiogenesis and Cytotoxic

Chemotherapy 47

Proteoglycan Mixture: Therapeutic Powerhouse 47

Features of VascuStatin 48

Angiogenesis Inhibition Versus Cytotoxic Therapy 48

Relationship Between Copper and Angiogenesis 48

Anti-Angiogenesis Action of Pencillamine 48

Outline of Steps Involved in Drug Discovery for Angiogenesis 49

Drug Delivery: Their Influence on Therapeutics 49

7. PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS 51

Angiogenesis Stimulators 51

Growth Factors 51

Angiogenic Stimulators in the Market 51

Table 7: Global Market for Angiogenesis Stimulators

(2009-2015): Geographic Regions Ranked by CAGR -USA, Europe,

and Rest of World (includes corresponding Graph/Chart) 51

Stimulators Exhibiting Profound Influence on Angiogenesis 51

Vascular Endothelial Growth Factor (VEGF) 51

VEGF and Their Influence on Diabetes and Diabetic Retinopathy 52

Fibroblast Growth Factors (FGFs) 52

Basic Fibroblast Growth Factor (bFGF) 52

Placental Growth Factor (PlGF) 52

Recombinant a4 Fragment 53

Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) 53

Angiogenin 53

Platelet Derived Endothelial Cell Growth Factor 53

Applications of Angiogenic Stimulators vis-a-vis Disease

Perspective 53

Cardiac Diseases 53

Wound Healing and Burns 54

Critical Limb Ischaemia 54

Status of Angiogenic Inducers 54

Angiogenic Therapies for Tissue Repair & Regeneration 54

Select Devices Supporting Therapeutic Angiogenesis 55

Angiogenesis in Ischemic Heart 55

Factors Influencing Ischemic Angiogenesis 55

Angiogenesis and CAD 55

Angiogenesis in Wound Healing 56

Factors Stimulating Wound Angiogenesis 56

Factors Impairing Wound Angiogenesis 56

Angiogenic Therapy Vs Conventional Therapy 57

Types of Angiogensesis 57

Excessive Angiogenesis 57

Insufficient Angiogenesis 57

Tumor Angiogenesis 57

Sequence of Actions 57

Angiogenesis and Tumor Progression 58

Oncogenes vis-a-vis Potential Pro-angiogenic Activities on

Tumor Angiogenesis 58

Role of Angiogenesis in Skin Diseases 58

Current State of Select Drugs & Their Targeted Application 59

Analysis of Developmental Activities Between Decades 59

Role of Enzymes and Inflammatory Cells in Angiogenesis 60

Angiogenic Imbalance Augments Retinal Neovascularization 60

Oncogenes & VE -cadherin - A Facilitating Role 60

8. PRODUCT APPROVALS AND LAUNCHES 61

Pfizer Obtains European Approval for SUTENT® to Treat

Pancreatic NET 61

Novartis Obtains FDA Approval of New Indication for Afinitor 61

FDA Approves Herceptin for Treating Metastatic Adenocarcinoma 61

Roche Introduces Avastin in China 62

Pfizer Japan Receives Clearance for Torisel in Japan 62

GSK Obtains European Commission's Conditional Marketing

Approval for Votrient 62

FDA Approves Tarceva® for Maintenance Treatment of NSCLC 62

FDA Approves GlaxoSmithKline's Votrient 63

European Commission Grants Clearance to Torisel for Mantle

Cell Lymphoma 63

Genetech Receives FDA Approval for Avastin in Renal Cell

Carcinoma 63

FDA Approves Bevacizumab as Second Line Treatment for

Glioblastoma 64

Novartis Obtains FDA Approval of Afinitor for Treating Renal

Cell Cancer 64

FDA Grants Clearance for Gleevec in Treatment of

Gastrointestinal Stromal Tumor 64

Celgene's Thalidomide Pharmion™ Receives EC Clearance for

Treating Multiple Myeloma 65

Genentech Obtains FDA Approval for Avastin in Breast Cancer 65

FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma 65

Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell

Carcinoma 66

OSI and Roche Announce Approval of Tarceva® in Japan 66

ImClone Obtains FDA Label Expansion for Erbitux®, as Third

Line Therapy in mCRC 66

REVLIMID® Obtains Swissmedic Authorization in Switzerland 66

REVLIMID® Receives Marketing Approval in European Union 67

Wyeth Obtains FDA Clearance for Marketing Torisel 67

Chugai Obtains Approval for Avastin in Japan 67

Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal

Cell Carcinoma 68

FDA Approves Herceptin in HER2-Overexpressing Breast Cancer

Treatment 68

Genentech Receives FDA Approval for Bevacizumab in Non-Small

Cell Lung Cancer 68

Amgen Obtains FDA Approval for Vectibix Treating mCRC 69

FDA Grants Marketing Approval for Lucentis in Wet AMD 69

Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma 69

FDA Approves Bevacizumab for Second Line Treatment of

Metastatic Colorectal Cancer 70

Celgene Obtains FDA's Accelerated Approval for THALOMID 70

Celgene Obtains sNDA Approval for THALOMID from FDA 71

ImClone Obtains FDA Clearance for Erbitux® in the treatment of

SCCHN 71

Pfizer's Sutent Receives FDA Nod for Treatment of

Gastrointestinal Stromal Tumor 71

Celgene Receives FDA's Subpart H Approval for Revlimid in

Myelodysplastic Syndromes 72

US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma 72

OSI Obtains FDA Approval for Tarceva™ In the Treatment of NSCLC 73

FDA Grants Approval to Erbitux® in the Treatment of Metastatic

Colorectal Carcinoma 73

AstraZeneca Obtains FDA Approval for Iressa in NSCLC Treatment 74

9. RECENT INDUSTRY ACTIVITY 75

Genentech to Carry Out Additional Trial of Avastin in Her2-

negative mBC 75

Pfizer to Seek regulatory Clearance for Axitinib in Europe and US 75

FDA to Withdraw Avastin's Approval for Breast Cancer 75

Eyetech Receives QTDP Grant To Develop Extended- Release

Formulation of Macugen® 75

sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned 76

EntreMed Enters into Financing Deal for ENMD-2076 Development 76

Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval 76

Gilead Sciences to Take Over CGI Pharma 77

Mersana Commences XMT-1107 Phase I Clinical Trial 77

Astellas Pharma Acquires OSI Pharmaceuticals 77

Roche to Conduct a Trial on Anti-Cancer Antibody TB-403 77

Mersana Therapeutics Inks License Agreement With Teva 78

Acceleron Publishes Pre-clinical Data Study on ACE-041 78

Antisense Raises Capital to Continue Phase III Trabedersen Trial 78

GSK Receives Positive Opinions from EMEA for Two Cancer Medicines 79

EMEA Issues Positive Opinion on GSK's Votrient 79

EMEA Issues Positive Opinion on GSK's Anti Cancer Drug

Candidate, Tyverb 79

Abbott Enters into Licensing Agreement with Pierre Fabre 80

Arno Therapeutics Inks Global Licensing Agreement with OSU 80

BI Initiates Late Stage Clinical Trials for Two Oncology Drug

Candidates 80

AnGes Obtains US FDA Approval for Phase III Trial of Collategene™ 80

Silence Therapeutics and Intradigm Merge 81

Mersana Launches First Phase of XMT-1107 Clinical Trial 81

ImClone Receives Complete Response Letter for Erbitux® sBLA

From FDA 82

Oxigene Releases Encouraging Data from OXi4503 Pre-clinical

Studies 82

Potentia Enters into Licensing and Purchase Option Deal with

Alcon 83

Quark Receives Additional Patents for RTP 801 Gene Targeting

Compounds 83

Simcere Enters into Collaboration Deal with OSI Pharmaceuticals 84

Pfizer Acquires Wyeth in Cash & Stock Merger 84

Gene Signal Releases Interim Results from Phase II Study on

GS-101 84

Onco to Conduct Second Phase Trial of Fuso's OTS102 85

Green Cross Obtains US FDA Approval for Greenstatin Clinical

Trial 85

OXiGENE Acquire Symphony ViDA 85

Roche Releases Positive Results from Phase III Trial of Lucentis 86

Pfizer Halts Phase III Sutent Study for Colorectal Cancer 86

Morphotek Obtains FDA Clearance for MORAb-004 IND Application 86

GlaxoSmithKline Files MAA for Pazopanib in EU 87

Roche Acquires Genentech 87

Fuso Commences Phase II/III Clinical Trail for OTS102 87

EntreMed to Funnel Resources on ENMD-2076 Development 87

OmegaGenesis Enters Into Collaboration with Mayo Clinic for

Angiogenesis Research 88

Eli Lilly Acquires ImClone Systems 88

EntreMed Demonstrates Antitumor Effects of ENMD-2076 88

EntreMed Collaborates with JSB for ENMD-2076 Business Development 88

Circadian Technologies Limited Acquires Vegenics 89

Fuso and OTS to Initiate Phase II Trial for OTS102 89

EntreMed Releases Pre-Clinical Findings of ENMD-2076 in

Multiple Myeloma 89

Merck Serono Inks Development and Licensing Agreement with

Bionomics 90

Roche Inks Licensing Agreement with ThromboGenics and

BioInvent for TB-403 90

Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug 91

Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116 91

Astellas and CoMentis Ink Agreement to Develop and

Commercialize Beta- Secretase Inhibitors 92

Kringle Pharma's NK4 Receives Patent Approval in Japan 92

UCB Releases Phase II Results of CDP791 in NSCLC Treatment 92

Celgene Takes Over Pharmion 92

REVLIMID® Obtains Orphan Drug Designation in Japan 93

TRACON Commences Phase I Clinical Trial on TRC105 93

Ark Therapeutics to Acquire Lymphatix 93

Access Takes Over Somanta 94

Pfizer Takes Over CovX 94

Callisto Restructures Licensing Agreement with Genzyme for

Atiprimod 94

EntreMed Receives FDA Approval for ENMD-2076 IND Application 95

EC Grants Orphan Medicinal Status to REVLIMID for Treatment of

CLC 95

Bristol-Myers Squibb Snaps Up Adnexus Therapeutics 95

Morvus Takes Over Two Companies 96

Merck Inks Agreement with BMS and ImClone for Erbitux®

Development And Commercialization 96

FDA Issues a Safety Labeling Update for Bevacizumab Drug 97

Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis

Inhibitor 97

CRC to Support Bionomics in BN069 Development 97

Peregrine Secures Licensing Rights for B2GP1 Angiogenesis

Inhibitor 97

AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point

in Phase III Study 98

ImClone Annuls Development Agreement with UCB 98

ArQule Partners with Kyowa Hakko in Cancer Compound 98

Samaritan Snaps Up Metastatin Pharmaceuticals 98

EU Approves euro 2 Million Grants for VASOPLUS Consortium 99

MGH Cancer Center Reports Results of AZD2171 Phase II Trial 99

AVEO Inks Exclusive Licensing Agreement with Kirin for Novel

Anti-Cancer Compound 99

Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement 100

Covalon Secures Perfusion's Gene Therapy Solutions 100

Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio 100

Biomira Takes Over ProIX Pharmaceuticals 100

FDA Gives Out Warning on Bevacizumab Drug 101

Athenagen Merges with Zapaq 101

Tigris Secures Global Licensing Rights to Develop and

Commercialize New Cancer Therapies 101

Bayer Yakuhin Files Marketing Application for Nexavar in Japan 101

Athenagen Purchases Assets of Osprey Pharmaceutical 102

Amgen Acquires Abgenix 102

Genmab Enters Exclusive Licensing Agreement with Bionomics 102

OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals 103

FDA Changes Labeling of Iressa, Limiting Use to NSCLC 103

Schering AG and Novartis Signs a Agreement to Commercialize

Angiogenesis Inhibitor, PTK787 103

Bausch & Lomb Signs an Option Agreement with PTC Therapeutics 104

Bausch & Lomb Receives License from Cephalon, Inc 104

Pharmacopeia Signs a Licensing Agreement with Allergan 104

Xantos Biomedicine and Cryptome Enters into Licensing Agreement 104

EntreMed Receives US Patent 105

FDA Issues Warning on Risks Associated with Bevacizumab 105

Compound Therapeutics Acquires Strategic Assets of Phylos 105

Sanofi Announces Plans to Acquire Aventis 105

ThromboGenics Enters into Collaborative Agreement with

Geymonat S.p.A. 105

AngioGenex Signs Development and Marketing Agreement with

BioCheck 106

Progen Industries Limited Bags Orphan Drug Status from US FDA 106

Regeneron Pharmaceuticals Initiates Phase I Clinical Trials

in Cancer 106

Roche Group to Undertake Expansion Program 106

Regeneron and Aventis Initiate a Clinical Development Program 106

EntreMed Signs Licensing Agreement with Celgene Corporation 106

Progen Industries Limited Receives EU Patent 107

Phylonix Pharmaceuticals Bags Phase II SBIR Grant 107

10. FOCUS ON SELECT GLOBAL PLAYERS 108

Abbott Laboratories (USA) 108

Adnexus Therapeutics, Inc. (USA) 108

AEterna Zentaris Inc. (Canada) 108

Amgen, Inc. (USA) 109

Angstrom Pharmaceuticals Inc. (USA) 109

AstraZeneca Plc. (UK) 110

Bayer HealthCare AG (Germany) 110

Callisto Pharmaceuticals, Inc. (USA) 111

Celgene Corporation (USA) 112

Celltech Group Plc. (UK) 112

Cephalon Inc. (USA) 112

Eisai Inc. (USA) 113

Eli Lilly And Company (USA) 113

ImClone Systems Inc. (USA) 114

EntreMed Inc. (USA) 114

GenVec Inc. (USA) 115

Genzyme Corp. (USA) 115

GlaxoSmithKline plc (UK) 116

Merck KGaA (Germany) 116

Novartis (Switzerland) 117

OSI Pharmaceuticals, Inc. (USA) 117

Eyetech, Inc. (USA) 118

Pfizer Inc. (USA) 119

Progen Industries (Australia) 119

Regeneron Pharmaceuticals 120

Roche (Switzerland) 121

Genentech Inc. (USA) 122

Chugai Pharmaceutical Co. Ltd. (Japan) 122

Silence Therapeutics 123

ThromboGenics Limited (Ireland) 123

11. GLOBAL MARKET PERSPECTIVE 125

Table 8: World Recent Past, Current & Future Analysis for

Angiogenesis Inhibitors & Stimulators by Geographic

Region/Country - US, Europe and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2003 through 2010 (includes corresponding Graph/Chart) 125

Table 9: World Historic Review for Angiogenesis Inhibitors &

Stimulators by Geographic Region/Country - US, Europe and

Rest of World Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 126

Table 10: World 11-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Geographic Region/Country -

Percentage Breakdown of Dollar Sales for US, Europe and Rest

of World Markets for Years 2005, 2010 and 2015 (includes

corresponding Graph/Chart) 126

Table 11: World Recent Past, Current & Future Analysis for

Angiogenesis Inhibitors by Geographic Region/Country - US,

Europe and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2015

(includes corresponding Graph/Chart) 127

Table 12: World Historic Review for Angiogenesis Inhibitors by

Geographic Region / Country - US, Europe and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 128

Table 13: World 11-Year Perspective for Angiogenesis

Inhibitors by Geographic Region/Country - Percentage Breakdown

of Dollar Sales for US, Europe and Rest of World Markets for

Years 2005, 2010 and 2015 (includes corresponding Graph/Chart) 128

Table 14: World Recent Past, Current & Future Analysis for

Angiogenesis Stimulators by Geographic Region/Country - US,

Europe and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2015

(includes corresponding Graph/Chart) 129

Table 15: World Historic Review for Angiogenesis Stimulators

by Geographic Region / Country - US, Europe and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 130

Table 16: World 11-Year Perspective for Angiogenesis

Stimulators by Geographic Region/Country - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

Markets for Years 2005, 2010 and 2015 (includes corresponding

Graph/Chart) 130

12. THE UNITED STATES 131

A.Market Analysis 131

US Spearheading the Angiogenesis Market 131

Angiogenic Inhibitors 131

List of FDA Approved Anti-Angiogenic Drugs 131

Pipeline Status By Disease 133

Anti-Angiogenesis Therapeutics In Phase III Development

for Renal Cell Carcinoma 133

Anti-Angiogenesis Therapeutics In Phase III Development

for Breast Cancer Treatment 133

Angiogenesis Stimulators 134

Historical Market Snapshots 134

Market Influencers 135

Types of Drug Approvals 135

New Drug Approval (NDA) 135

Orphan Drug Act 135

Benefits Derived on Successful Grant of 135

Orphan Drug Status 135

Angiogenesis Foundation 135

Key Role of the Foundation in Angiogenesis 136

The Rising Concern 136

Cancer 136

Cancer Statistics in US 136

A Picture of Colon Cancer in the US 136

Pancreatic Cancer 136

Vital Statistics 137

Table 17: New Cancer Cases in the US By Affected Site:

2009 137

Table 18: New Cancer Cases in Males in US by Leading

Site: 2009 (includes corresponding Graph/Chart) 139

Table 19: New Cancer Cases in Females in US by Leading

Site:2009 (includes corresponding Graph/Chart) 140

Table 20: Cancer Related Deaths in the US By Affected

Site:2009 141

Table 21: Cancer Related Deaths in Males in US by Leading

Site: 2009 (includes corresponding Graph/Chart) 143

Table 22: Cancer Related Deaths in Females in US by

Leading Site: 2009 (includes corresponding Graph/Chart) 144

AMD and DME Incidence in the US 144

Rheumatoid Arthritis: Another Emerging Threat 144

Diabetic Retinopathy 145

Coronary Artery Disease (CAD) 145

Myocardial Infarction Statistics in the US 145

Peripheral Arterial Disease 145

B.Market Analytics 146

Table 23: US Recent Past, Current & Future Analysis for

Angiogenesis Inhibitors & Stimulators by Product

Segments-Angiogenesis Inhibitors and Angiogenesis

Stimulators Markets Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2015

(includes corresponding Graph/Chart) 146

Table 24: US Historic Review for Angiogenesis Inhibitors &

Stimulators by Product Segments- Angiogenesis Inhibitors and

Angiogenesis Stimulators Markets Independently Analyzed

with Annual Revenues in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) 147

Table 25: US 11-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Product Segments - Percentage

Breakdown of Dollar Sales for Angiogenesis Inhibitors &

Stimulators for Years 2005, 2010 and 2015 147

13. EUROPE 148

A.Market Analysis 148

Facet of Angiogenesis in the European Market 148

Angiogenesis Market - A Historic Perspective 148

Cancer Trends 148

Table 26: Cancer Incidence in Europe by Site (2009)

(includes corresponding Graph/Chart) 149

B.Market Analytics 150

Table 27: European Recent Past, Current & Future Analysis

for Angiogenesis Inhibitors & Stimulators by Product

Segments-Angiogenesis Inhibitors and Angiogenesis

Stimulators Markets Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2015

(includes corresponding Graph/Chart) 150

Table 28: European Historic Review for Angiogenesis

Inhibitors & Stimulators by Product Segments- Angiogenesis

Inhibitors and Angiogenesis Stimulators Markets

Independently Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 151

Table 29: European 11-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Product Segments - Percentage

Breakdown of Dollar Sales for Angiogenesis Inhibitors &

Stimulators for Years 2005, 2010 and 2015 151

14. REST OF WORLD 152

A.Market Analysis 152

Angiogenesis Market - Making a Positive Move 152

Japanese Market 152

Quest for New Opportunities 152

B.Market Analytics 153

Table 30: Rest of World Recent Past, Current & Future

Analysis for Angiogenesis Inhibitors & Stimulators by

Product Segments-Angiogenesis Inhibitors and Angiogenesis

Stimulators Markets Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2015

(includes corresponding Graph/Chart) 153

Table 31: Rest of World Historic Review for Angiogenesis

Inhibitors & Stimulators by Product Segments- Angiogenesis

Inhibitors and Angiogenesis Stimulators Markets

Independently Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 154

Table 32: Rest of World 11-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Product Segments - Percentage

Breakdown of Dollar Sales for Angiogenesis Inhibitors &

Stimulators for Years 2005, 2010 and 2015 154

COMPETITIVE LANDSCAPE

Total Companies Profiled: 72 (including Divisions/Subsidiaries - 84)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 50

Canada 2

Japan 3

Europe 21

France 2

Germany 5

The United Kingdom 5

Italy 3

Rest of Europe 6

Asia-Pacific (Excluding Japan) 8

------------------------------------------

To order this report:

: Global Angiongenesis Inhibitors and Stimulators Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November ... Business Conference will bring together over 500 top healthcare leaders for a night and ... The conference, organized by MBA students of the University of Pennsylvania’s Wharton School, will ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Tunnell Consulting, ... Based in Paris, he will focus on acquiring new accounts and work closely ... , “Fred brings to our European clients more than 15 years ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/8/2016)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... companies in the TSX Venture 50 TM . ... TSX Venture Exchange, in each of five major industry sectors ... life sciences, diversified industries and technology – based on a ... market cap growth, trading volume and analyst coverage. All data ...
Breaking Biology Technology:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/8/2016)... Connecticut , January 8, 2016 ... m-commerce market and WorldVentures ® , a privately held ... and an Inc. 5000 fastest-growing company announced ... strategic investment of $2 million in Nxt-ID to develop ... based on Nxt-ID,s Wocket ® , a unique smart ...
Breaking Biology News(10 mins):